# To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

> **NCT04253236** · PHASE2 · TERMINATED · sponsor: **Immunovant Sciences GmbH** · enrollment: 5 (actual)

## Conditions studied

- Warm Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** RVT-1401 680 mg/weekly
- **DRUG:** RVT-1401 340 mg/weekly

## Key facts

- **NCT ID:** NCT04253236
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-11
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04253236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04253236, "To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04253236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*